A Part D Subsidy Expires After 2026, and Premiums Bite
A federal program has been quietly holding down stand-alone Medicare Part D premiums. It ends after 2026 — and retirees who stayed with Original Medicare are already paying four times what Advantage drug…
A retiree who kept a stand-alone Medicare Part D drug plan alongside Original Medicare is paying four times what Medicare Advantage drug coverage costs, a gap that a federal premium-cushioning program has been masking and that will be exposed when the program ends after 2026, according to 24/7 Wall St.
One retiree's arithmetic is about to become a lot of retirees' arithmetic. He stayed with Original Medicare and bought a stand-alone prescription drug plan to go with it — the traditional, unbundled route through the program. That drug plan now costs four times what drug coverage costs inside a Medicare Advantage plan. And the federal cushion that has kept the gap from being even wider expires after 2026.
The case was reported by 24/7 Wall St, and the detail that matters most is not the retiree's premium. It is the structural point behind it: a temporary federal program has been suppressing the visible price of stand-alone Part D coverage, and when the suppression stops, the price that shows up on the statement is the price that was always there.
Two doors into drug coverage, priced very differently
Medicare beneficiaries reach prescription coverage by one of two routes. The first is Original Medicare — the government-run hospital and medical benefit — paired with a separate, privately sold stand-alone drug plan. The enrollee pays that plan's premium directly, on top of the standard Part B premium, and typically buys a supplemental policy as well to blunt cost-sharing.
The second is Medicare Advantage: a private plan that replaces Original Medicare and bundles drug coverage inside it. Insurers can fund that bundled drug benefit out of the payments they receive for managing the whole beneficiary, which is why the drug portion of an Advantage plan can carry a headline premium far below what a stand-alone plan must charge to cover the same pharmacy risk on its own. In this retiree's case, the ratio is four to one.
That is not a like-for-like comparison of medical value, and no one should read it as one. Advantage plans come with networks, prior authorization and referral rules that Original Medicare does not impose. What the four-to-one figure does capture is the cash difference a retiree sees each month — and cash differences are what drive enrollment decisions during open season.
What the expiring cushion actually does
The federal program at the center of the story works by absorbing part of the premium increase that stand-alone drug plans would otherwise pass through to enrollees. Its purpose was stabilization: to stop sticker shock from pushing beneficiaries out of stand-alone coverage in a single year while the market adjusted to a redesigned drug benefit.
Stabilization programs have a habit of becoming invisible. Because the cushion shows up as a premium that did not rise rather than as a credit on a bill, most enrollees have no way of knowing it exists. That is precisely the problem. A retiree who has watched a stand-alone premium creep up modestly for several years has been reading a managed number, not a market number, and has drawn a false conclusion about the trajectory of the cost.
When the program ends after 2026, the premium that appears for the following plan year is the unmanaged one. The lead does not put a dollar figure on the per-member subsidy, and this article will not invent one — but the direction is not in doubt, and neither is the timing.
Who feels it and when the decision lands
The exposed group is specific: people enrolled in stand-alone Part D plans alongside Original Medicare who do not qualify for low-income assistance and who therefore pay the full premium themselves. Within that group, the ones most at risk of a painful surprise are those who have never comparison-shopped since they first enrolled — a large share of Medicare beneficiaries, by every measure of switching behavior the program has ever produced.
Three practical implications follow.
- The annual notice matters more this year than usual. Plans send enrollees a document describing next year's premium, deductible and formulary changes. In a year when a subsidy is unwinding, that document is the earliest concrete signal of the new cost.
- The premium is not the only variable. A cheaper plan with a worse formulary — the list of drugs it covers and at what tier — can cost more in total for someone on a specific maintenance medication. The comparison that counts is total annual outlay, premium plus deductible plus expected copays, not the monthly headline.
- Switching to Advantage is not a free lunch. Moving to a bundled plan to capture the lower drug cost also means accepting network limits and, critically, giving up the ability to return easily to a supplemental Medigap policy in many states. That is a one-way door for some retirees, and it should be priced as one.
The insurers on the other side of the trade
The stand-alone Part D market is concentrated among a handful of large carriers, and their economics change when the stabilization payments stop. Two things can happen: they raise premiums to cover the risk, or they thin the plan lineup and let enrollees migrate into the Advantage products where the same members are more profitably managed. Both outcomes push volume from the unbundled market to the bundled one, which is the direction enrollment has been traveling for years anyway. The end of the cushion does not create that migration — it accelerates it.
For investors, the read-through is about mix rather than headline membership. A carrier that converts a stand-alone drug enrollee into a full Advantage member captures the whole beneficiary rather than a slice of pharmacy risk. Whether that trade is favorable depends on medical cost trend, which has been the sector's sore point. None of the specific carrier exposures are quantified in the reporting behind this story, so treat the direction as a framework, not a forecast.
Market backdrop as the policy clock runs down
The equity market gave no sign of caring on the day. The S&P 500 tracker (NYSEARCA: SPY) closed at $777.88, up 0.70% from the prior close of $772.49, as of the last trade at 20:00 GMT on Aug. 13, 2026. The Nasdaq 100 fund (NASDAQ: QQQ) closed at $732.07, up 1.16%, and the Dow 30 vehicle (NYSEARCA: DIA) finished at $537.91, up 0.14%. Broad indexes rarely price a benefit-design change that lands on household budgets rather than corporate income statements in the same quarter.
That is the asymmetry worth holding onto. A subsidy expiration is a slow, scheduled, well-telegraphed event at the policy level and an abrupt one at the mailbox level. The retirees who read their annual notice carefully this autumn will have options. The ones who assume next year looks like this year will find out in January, when the first premium of the new plan year clears their account.
What to watch between now and open enrollment
Three markers will tell the story. First, the premium filings and plan-lineup announcements from the large stand-alone Part D carriers for the year after 2026 — that is where the size of the unwind becomes visible. Second, whether Congress or the agency extends or replaces the stabilization mechanism, which has happened before with temporary programs and cannot be ruled out. Third, the enrollment shift itself: if stand-alone membership drops sharply in the next open enrollment period, the four-to-one gap described in this single retiree's case will have proved to be the market signal it looks like.
Key facts
- Cost gap: Stand-alone Part D plan costs four times Advantage drug coverage
- Subsidy deadline: Federal premium-cushioning program ends after 2026
- S&P 500 (SPY): $777.88, +0.70%, last trade 20:00 GMT Aug 13, 2026
- Most exposed: Original Medicare enrollees paying full stand-alone Part D premiums
Frequently asked questions
What is a stand-alone Medicare drug plan?
It is a private prescription drug plan bought separately to sit alongside Original Medicare, the government-run hospital and medical benefit. The enrollee pays its premium directly, on top of the standard Part B premium. It is the unbundled route to drug coverage, as opposed to a Medicare Advantage plan that includes drug coverage inside a single private policy.
Why does Advantage drug coverage cost so much less?
Medicare Advantage insurers receive payment for managing a beneficiary's entire care and can fund the drug benefit out of that broader arrangement. A stand-alone plan must cover pharmacy risk on its own premium alone. In the case reported by 24/7 Wall St, that structural difference produced a four-to-one cost gap for one retiree.
What happens when the federal cushion ends after 2026?
The program has been absorbing part of the premium increases stand-alone Part D plans would otherwise pass to enrollees. Once it lapses after 2026, the premium shown for the following plan year reflects the unmanaged cost. The reporting does not put a dollar figure on the per-member subsidy, but the direction of premiums is upward.
Should a retiree switch to Medicare Advantage to save money?
Not automatically. Advantage plans use networks, referrals and prior authorization that Original Medicare does not, and in many states leaving Original Medicare makes it hard to buy a Medigap supplemental policy later. The lower drug premium is real, but so are the trade-offs. Total annual outlay and drug formulary coverage matter more than the monthly headline.
How would someone find out their premium is rising?
Each plan sends enrollees an annual notice describing the coming year's premium, deductible and formulary changes before open enrollment. In a year when a stabilization subsidy is unwinding, that document is the earliest concrete signal of the new cost, and it is worth reading line by line rather than filing away.
Which insurers are affected by the subsidy expiration?
The stand-alone Part D market is concentrated among several large carriers. When stabilization payments stop, they can raise premiums or trim plan lineups and steer members into their Medicare Advantage products, where the whole beneficiary is captured. The specific carrier exposures were not quantified in the reporting behind this story.
Sources
Photo: Kampus Production · Pexels Licence — source
